The COVID Vaccines Are aTriumph of Globalization
div class=lead mb-3 spacer--nomargin--last-child text-default
pDear Captiolistae, /p
/div
,
div class=mb-3 spacer--nomargin--last-child text-default
pSeemingly everywhere you turn these days, someone is expressing doubts about “globalization” and lamenting its impact on American workers. This obviously has been anbsp;theme of the Trump administration and its America First approach to U.S. trade and immigration policy, but you may be surprised to learn that anbsp;lot of Biden folks have been saying similar stuff in recent years (emsee/em,nbsp;eme.g./em, this recentnbsp;ema href=https://protect-us.mimecast.com/s/JPaXCwp79KcGK7PoTV7I6T?domain=urldefense.proofpoint.com target=_blankWall Street Journal/anbsp;/empiece). And, unsurprisingly, the media—always on the lookout for anbsp;sympathetic victim of capitalist greed—has been similarly focused on globalization’s alleged harms./p
pIndeed, when articles like thenbsp;emWSJ/emnbsp;piece above are written or political speeches are made, the sources usually couch any benefits of globalization—assuming they speak of them at all—in terms of consumers (the proverbial “cheap T‐shirt” made abroad) or corporations and their shareholders (insert evils of capitalism here). Few stop to consider the broader benefits that the relatively free movement of goods, services, labor, capital, and ideas across national borders confers upon each of us and the nation or world more broadly./p
pSo that’s what we’ll do today, looking at perhaps the best recent example of such globalization benefits: the Pfizer/BioNTech and Moderna COVID-19 vaccines that we’ll hopefully soon have injected in our arms. As you’ll see, every part of the vaccines—from corporate leadership to investment to research and development to production and distribution—depends on “globalization”nbsp;emand/emnbsp;would suffer from government attempts to block it./p
pstrongThe Companies and Their Leaders/strong/p
pBioNTech, anbsp;German company with an office in Cambridge, Massachusetts, wasnbsp;a href=https://www.nytimes.com/2020/11/10/business/biontech-covid-vaccine.html?s=03#click=https://t.co/JBKYjxuWqI target=_blankfounded/anbsp;by Dr. Ugur Sahin and his wife, Dr. Özlem Türeci—both of Turkish descent. The former immigrated to Germany from Turkey with his parents when he was 4 (his father worked in anbsp;German auto plant); the latter was born in Germany to Turkish immigrants. In 2019, Dr. Sahin won the Iranian Mustafa Prize, which is awarded to Muslims in science and technology./p
pPfizer, the New York‐based multinational with offices around the world, is run by Albert Bourla, anbsp;native of Greece who began at the company’s Greek outpost in the early 1990s. Bourla worked across Europe before moving to Pfizer’s global headquarters in Manhattan and later becoming CEO. Other top Pfizer execs include Angela Hwang, anbsp;South Africa native; Mikael Dolsten, anbsp;Swede; and Rod MacKenzie and John Young, both from the U.K.. Oh, and Pfizer was started in New York by two German immigrants—Charles Pfizer and Charles Erhart—in 1849./p
pBoston‐basednbsp;a href=https://marginalrevolution.com/marginalrevolution/2020/11/more-immigrant-founders-and-co-founders-in-this-case-moderna.html?utm_source=feedburneramp;utm_medium=feedamp;utm_campaign=Feed%3A+marginalrevolution%2Ffeed+%28Marginal+Revolution%29 target=_blankModerna/a’s co‐founder and chairman is Noubar Afeyan, anbsp;two‐time immigrant. Born to Armenian parents in Lebanon, he immigrated as anbsp;teenager to Canada and then moved to the United States after college to earn his Ph.D. from the Massachusetts Institute of Technology (MIT). Stéphane Bancel, Moderna’s CEO, also immigrated to America (from France) for grad school. The company’s other co‐founder, Derrick Rossi, was born in Canada and is here on an H-1B visa. Moderna’s chief medical officer, Tal Zaks, is Israeli and also here on an employment‐based visa. The chief digital and operational excellence officer is from France, and their chief technical operations and quality officer is from Spain. (Seriously, it’s like the UN over there.)/p
pFinally, the Trump administration’s point man for the vaccine, Operation Warp Speed chief Moncef Slaoui, is anbsp;Moroccan‐born Muslim immigrant from Belgium (and now anbsp;U.S. citizen) who was formerly at British multinational pharmaceutical giant GlaxoSmithKline, serving as chairman of its vaccines division and global head of Ramp;D. (He was also on Moderna’s board of directors prior to joining OWS.)/p
pstrongThe Investment/strong/p
pAll three companies are also major beneficiaries of global capital markets. Moderna was anbsp;a href=https://news.crunchbase.com/news/with-flagship-behind-it-moderna-quickly-scaled-from-startup-to-world-changing-biotech/ target=_blankconcept‐stage company/anbsp;for Boston area biotech venture capital firm Flagship Pioneering, which “has anbsp;history of building innovative biotech companies in‐house,” according to Crunchbase News’ Joanna Glassner. It opened as anbsp;private company in 2012 with a $40 million VC jump‐start, and then “raised over $2.7 billion in venture and growth funding, with backing from anbsp;mix of venture capital firms and corporate investors.” Moderna alsonbsp;a href=https://www.genengnews.com/topics/omics/moderna-wins-initial-20m-grant-from-gates-foundation/ target=_blankreceived millions/anbsp;from the Gates Foundation in 2016 to develop therapeutics based on messenger RNA to treat HIV. It went public in December 2018.nbsp;/p
pBefore the pandemic,nbsp;a href=https://www.nytimes.com/2020/11/10/business/biontech-covid-vaccine.html?s=03#click=https://t.co/JBKYjxuWqI target=_blankBioNTech/anbsp;used various global private share listings to raisenbsp;a href=https://investors.biontech.de/news-releases/news-release-details/biontech-raises-usd-325-million-upsized-series-b-financing target=_blankhundreds of millions of dollars/anbsp;and create the 1,800-person company. The company also benefited from its founders’nbsp;a href=https://www.biospace.com/article/little-known-ganymed-grabs-a-1-4-billion-buyout-deal-from-astellas-/ target=_blank$1.4 billion sale/anbsp;of their previous company to Japan‐based Astellas Pharma in 2016. Last year, the Gates Foundation invested $55 million to fund BioNTech’s work on HIV and tuberculosis, and the company went public. (Unsurprisingly, those shares have soared this year.)/p
pPfizer, of course, is anbsp;giant multinational corporation whose global revenues and investor base (a $224 billion market capitalization, as of Monday) allowed it to single‐handedly fund, at anbsp;cost ofnbsp;a href=https://www.axios.com/pfizer-ceo-says-he-wouldve-released-vaccine-data-before-election-if-possible-a4f0c822-bf49-4a04-ac7f-5275c8d895b4.html?stream=top target=_blankabout $2 billion/a, the BioNTech vaccine’s testing, manufacturing and distribution—without significant government assistance, by the way—and zoom past Moderna for the lead in the COVID-19 vaccine race.nbsp;a href=https://twitter.com/scottlincicome/status/1333456993756049409 target=_blankFor example/a, “both Pfizer and Moderna were facing the problem of too few minority volunteers, but Pfizer had the deep pockets to solve it. The firm expanded its trial from 30,000 to 44,000, anbsp;decision… estimated cost the firm hundreds of millions of dollars.” As Pfizer CEO Bourla explained of the company’s $2 billion risk, “if it fails, it goes to our pocket. And at the end of the day, it’s only money. That will not break the company.” Must be nice./p
pstrongThe Research and Development/strong/p
pThe vaccines’ research and development unsurprisingly followed the medical field’snbsp;a href=https://www.future-science.com/doi/10.4155/ppa-2019-0017 target=_blanklongstanding model/anbsp;of global collaboration. For example, though Moderna’s researchers famouslynbsp;a href=https://www.nytimes.com/2020/11/21/us/politics/coronavirus-vaccine.html target=_blankneeded/anbsp;only two days to design their vaccine, they relied on anbsp;genetic map of the virus that was created by Chinese researcher Yong‐Zhen Zhang and his team, including Australian Eddie Holmes. That map was released to the world on January 10nbsp;in an open‐source depository and notified to the world via anbsp;a href=https://twitter.com/edwardcholmes/status/1215802670176276482 target=_blanksingle Holmes tweet/anbsp;on January 11. Asnbsp;a href=https://zeynep.substack.com/p/the-pandemic-heroes-who-gave-us-the target=_blankchronicled/anbsp;by Zeynep Tufecki, these actions “sent shockwaves through the global scientific community” and were quite heroic: “the sequence was published ten days before China acknowledged the severity of the problem… [and] while China—and the WHO, which depended on China for information—were still downplaying what was going on, in their official statements.”nbsp;/p
pMeanwhile, yet another immigrant, Hungarian‐born Katalin Karikó, wasnbsp;a href=https://t.co/7cMKM7ZLHS?amp=1 target=_blankresponsible/anbsp;for the messenger RNA (“mRNA”) technology behind both the Moderna and BioNTech vaccines:/p
/div
,
blockquote class=blockquote
div
pAfter anbsp;decade of research at two U.S. universities, including with Drew Weissman, her “longtime collaborator at Penn,” Karikó solved the problem plaguing mRNA, namely that the body fought the new chemical after an injection. “Karikó and Weissman [created] … anbsp;hybrid mRNA that could sneak its way into cells without alerting the body’s defenses,” writes Garde. “And even though the studies by Karikó and Weissman went unnoticed by some, they caught the attention of two key scientists—one in the United States, another abroad—who would later help found Moderna [Rossi] and Pfizer’s future partner, BioNTech.”/p
/div
/blockquote
cite
/cite
,
div class=mb-3 spacer--nomargin--last-child text-default
pKarikó today lives and works in the United States as BioNTech’s senior vice president./p
pSpeaking of, BioNTech firstnbsp;a href=https://biontech.de/sites/default/files/2019-08/20180816_BioNTech-Signs-Collaboration-Agreement-with-Pfizer.pdf target=_blankpartnered/anbsp;with Pfizer in 2018 on developing anbsp;flu vaccine using the mRNA technology, and thatnbsp;a href=https://www.nytimes.com/2020/11/10/business/biontech-covid-vaccine.html?s=03#click=https://t.co/JBKYjxuWqI target=_blankspawned/anbsp;their COVID-19 collaboration and the CEOs’ unlikely friendship (emphasis mine):/p
/div
,
blockquote class=blockquote
div
pAfter BioNTech had identified several promising vaccine candidates, Dr. Sahin concluded that the company would need help to rapidly test them, win approval from regulators and bring the best candidate to market. BioNTech and Pfizer had been working together on anbsp;flu vaccine since 2018, and in March, they agreed to collaborate on anbsp;coronavirus vaccine./p
pSince then, Dr. Sahin, who is Turkish, has developed anbsp;friendship with Albert Bourla, the Greek chief executive of Pfizer. The pair said in recent interviews that they had bonded over their shared backgrounds as scientists and immigrants./p
p“We realized that he is from Greece, and that I’m from Turkey,” Dr. Sahin said, withoutnbsp;strongmentioning their native countries’ long‐running antagonism/strong. “It was very personal from the very beginning.”/p
/div
/blockquote
cite
/cite
,
div class=mb-3 spacer--nomargin--last-child text-default
pGotta love it./p
pstrongThe Production/strong/p
pProduction of the vaccines will utilize global supply chains and multinational manufacturing capacity that was both created for COVID-19 and already in place. Pfizer, for example, hasnbsp;a href=https://www.pfizer.com/sites/default/files/investors/financial_reports/annual_reports/2017/assets/media/Pfizer-infographic-US-ManufacturingSites.pdf target=_blanknumerous/anbsp;U.S.-based manufacturing, supply, and distribution sites, and chose three American facilities for the COVID vaccine: St. Louis, Missouri; Andover, Massachusetts; and Kalamazoo, Michigan. Those will benbsp;a href=https://twitter.com/scottlincicome/status/1334667507362357249?s=20 target=_blanksupplemented/anbsp;by Pfizer’s factory in Puurs in Belgium, which will serve Europe and will supplement the Kalamazoo plant. BioNTech also has substantial mRNA manufacturing capacity in Germany and received anbsp;German government grant to expand that production. The companies project that their combined manufacturing network will be able to supply about 50 million vaccine doses in 2020 and up to 1.3 billion doses by the end of 2021./p
pPfizer’s factories will get raw materials from both the United States and Europe—part of anbsp;complexnbsp;a href=https://twitter.com/scottlincicome/status/13346713 target=_blanksupply chain/anbsp;that Pfizer has established for production and delivery of the vaccine. Thenbsp;emFinancial Times/em a href=https://www.ft.com/content/b5d03854-39bb-48cd-9a01-5fb2a0dfbba8 target=_blankreports/anbsp;that the BioNTech/Pfizer vaccine will be encapsulated in “lipid nanoparticles”—tiny droplets that “enclose and protect the fragile genetic instructions as they are manufactured, transported and finally injected into people”—sourced fromnbsp;a href=https://acuitastx.com/technology/lipid-nanoparticles/ target=_blankAcuitas/a, anbsp;specialistCanadian company. (Britain’s Croda Internationalnbsp;a href=https://cen.acs.org/business/outsourcing/Pfizer-Moderna-ready-vaccine-manufacturing/98/i46 target=_blankmay also supply/anbsp;Pfizer with lipids from anbsp;site it recently acquired in Alabama.) Pfizer has also reportedly contracted with Switzerland’s Siegfried for large‐scale filling and packaging in Hameln, Germany./p
pWhile most of Pfizer’s and BioNTech’s production is in‐house, Moderna will outsource most of its manufacturing to Swiss pharmaceutical manufacturernbsp;a href=https://twitter.com/scottlincicome/status/1333783651855650818 target=_blankLonza/a, which “is building out capacity for 400M doses anbsp;year—300M from three production lines in Visp, Switzerland, and 100M in New Hampshire…” and could add even more capacity in Switzerland next year. German firm CordenPharma willnbsp;a href=https://cen.acs.org/business/outsourcing/Pfizer-Moderna-ready-vaccine-manufacturing/98/i46 target=_blanksupply/anbsp;Moderna’s lipids from three European facilities and its largest one in Boulder, Colorado. Moderna also has contracted with New Jersey‐based Catalent and Spain’s Laboratorios Farmacéuticos Rovi to provide vial filling and packaging support./p
pstrongThe Distribution/strong/p
pFinally, the vaccines will utilize anbsp;massive “cold chain” distribution network to deliver doses around the world. Pfizernbsp;a href=https://www.wsj.com/articles/pfizer-sets-up-its-biggest-ever-vaccination-distribution-campaign-11603272614?mod=article_inline target=_blankpiggybacked/anbsp;off its previous experience with global refrigerated distribution and set up cold storage systems in the United States and Germany, including the creation of suitcase‐sized “a href=https://www.cbsnews.com/news/covid-vaccine-pfizer-cool-box-transport/ target=_blankcool boxes/a,” to transport the vaccine. Pfizer also partnered with cargo companies (FedEx, UPS and DHL) andnbsp;a href=https://www.wsj.com/articles/united-begins-flying-pfizers-covid-19-vaccine-11606512293 target=_blankUnited Airlines/anbsp;(which would fly between Brussels and Chicago) to deliver the vaccine. Other U.S. and foreign commercial airlines, which have spare capacity due to COVID travel restrictions and depressed demand, arenbsp;a href=https://www.bloomberg.com/news/articles/2020-11-29/airlines-face-mission-of-the-century-in-distributing-vaccines target=_blankalso getting involved/a. The International Air Transport Association “estimates that the equivalent of 8,000 loads in anbsp;110‐ton capacity Boeing 747 freighter will be needed for the airlift, which will take two years to supply some 14 billion doses, or almost two for every man, woman and child on Earth.”/p
pThe U.S. government took anbsp;different approach and selected Texas‐based global medical goods wholesaler McKesson Corp. to distribute other COVID-19 vaccines, including Moderna’s doses, through Operation Warp Speed. With offices throughout North America, as well as in Australia, Ireland, France, the Netherlands, and the United Kingdom, McKesson has decades of experience delivering drugs around the world./p
pGlobal cargo companies’ recent efforts to prepare for the vaccines arenbsp;a href=https://www.wsj.com/articles/from-freezer-farms-to-jets-logistics-operators-prepare-for-a-covid-19-vaccine-11598639012?mod=article_inline target=_blankimpressive/a:/p
ul
li
p“UPS is lining up rows of freezer units, packed together in what the company calls freezer farms, for vaccines requiring minus 80 degrees Celsius in Louisville, Ky., and Venlo in the Netherlands, near the delivery giant’s global air hubs”;nbsp;/p
/li
li
p“Lufthansa Cargo, the freight arm of Deutsche Lufthansa AG, sped up construction of two pharmaceutical storage facilities, at Chicago’s O’Hare International Airport and Munich Airport, in part to be ready for anbsp;vaccine”; andnbsp;/p
/li
li
p“DHL Global Forwarding is evaluating plans to transport vaccines through anbsp;combination of air and expedited ocean shipping, which the company has used to deliver personal protective equipment…”/p
/li
li
p“KLM workers are gearing up for anbsp;surge next year in COVID-19 vaccine cargos that will need to be flown around the world at ultra‐low temperatures. Anbsp;major hub for pharmaceutical products, Schiphol [Holland] has already handled some of the vaccines being used in trials and KLM’s boss is confident its ‘cold chain’ operations will cope with the influx of cargos as mass inoculations start in earnest.”/p
/li
/ul
pAll of these efforts, however, rely in large part on the massive and mind‐numbingly complex global shipping, storage, and logistics systems and capacity already in place due to global trade. (And don’t even get me started on hownbsp;a href=https://www.researchgate.net/figure/Boeings-global-supply-chain_fig1_322270152 target=_blankthe jets/anbsp;are made.) As logistics expert Brian Bourkenbsp;a href=https://www.wsj.com/articles/from-freezer-farms-to-jets-logistics-operators-prepare-for-a-covid-19-vaccine-11598639012?mod=article_inline target=_blanktold/anbsp;thenbsp;emWall Street Journal/em, global vaccine distribution will be “the equivalent of every iPhone, Galaxy and PlayStation launch all at the same time.” If we didn’t already have the networks and technology that invisibly developed over decades to deliver those (and other) goods, shipping the COVID vaccines at the projected speed and scale would have been impossible./p
pstrongSumming It All Up/strong/p
pLast week, Vice President Pencenbsp;a href=https://twitter.com/thehill/status/1334724360863670274?s=20 target=_blankcredited/anbsp;the COVID-19 vaccine rollout in the United States to President Trump’s leadership and Operation Warp Speed, telling his audience thatnbsp;only in America “could you see the kind of innovation that’s resulted in the development of anbsp;vaccine in record time.”/p
pSurely, some U.S. government vaccine efforts, for example regulatory relief or advance purchase agreements, warrant praise, and there are plenty of Americans and American institutions involved. But the sections above show that the BioNTech/Pfizer and Moderna vaccines rely less on anbsp;handful of government officials or any one nation than on the global flow of knowledge, capital, people, and goods—as well as the dense distribution networks and free market policies facilitating those movements—that existed long before we’d ever heard of COVID-19. Even this “globalization,” however, really just scratches the surface. Inbsp;didn’t mention, for example, the multinational testing and research teams, or the other vaccines being produced by similar collaborations (some of which Inbsp;documented in anbsp;a href=https://www.cato.org/blog/covid-19-vaccine-needs-globalization-therefore-so-does-trump-administration?queryID=fcea336e6078b7d7b2f1fa79e94c8178 target=_blankrecent blog post/a). Nor did Inbsp;detail all of the little things—likenbsp;a href=https://www.uschamber.com/series/above-the-fold/how-trade-immigration-and-global-supply-chains-will-defeat-the-pandemic target=_blankglass vials, “adjuvants,” and dry ice/anbsp;(or the machines that make or transport these items)—that we often ignore but without which the speedy development and distribution of the COVID-19 vaccines wouldn’t be possible.nbsp;/p
pDocumenting all of these benefits would take anbsp;book, not anbsp;newsletter (if it were even possible at all). But we can start by at least recognizing that they—and the organic processes by which they’re developed—exist, instead of pretending that “globalization” is all about cheap t‐shirts and corporate greed.nbsp;/p
pstrongChart(s) of the Week/strong/p
pThe “Expensive Exodus” was well‐underway before COVID (a href=https://t.co/ibKMrwklEW?amp=1 target=_blanksource/a):/p
/div
,
figure class=figure overflow-hidden figure--default figure--no-caption responsive-embed-no-margin-wrapper
div class=figure__media
img width=700 height=607 alt=lcome-1.jpg class=lozad component-image loading=lazy data-srcset=/sites/cato.org/files/styles/pubs/public/2020-12/lcome-1.jpg?itok=pCtixgSS 1x, /sites/cato.org/files/styles/pubs_2x/public/2020-12/lcome-1.jpg?itok=oTYlRlWV 1.5x data-src=/sites/cato.org/files/styles/pubs/public/2020-12/lcome-1.jpg?itok=pCtixgSS typeof=Image /
/div
/figure
,
figure class=figure overflow-hidden figure--default figure--no-caption responsive-embed-no-margin-wrapper
div class=figure__media
img width=700 height=607 alt=lcome-2.jpg class=lozad component-image loading=lazy data-srcset=/sites/cato.org/files/styles/pubs/public/2020-12/lcome-2.jpg?itok=6VkP0COK 1x, /sites/cato.org/files/styles/pubs_2x/public/2020-12/lcome-2.jpg?itok=Pyr4iCQ_ 1.5x data-src=/sites/cato.org/files/styles/pubs/public/2020-12/lcome-2.jpg?itok=6VkP0COK typeof=Image /
/div
/figure
,
div class=mb-3 spacer--nomargin--last-child text-default
pstrongThe Links/strong/p
pa href=https://www.cato.org/blog/some-perspective-chinese-control-rare-earth-minerals?utm_source=twitteramp;utm_medium=social-mediaamp;utm_campaign=addtoany target=_blankMe on “rare earth” minerals and China/a/p
pa href=https://voxeu.org/article/recent-fall-fdi-flows-us target=_blankWhat explains the recent decline in U.S. foreign direct investment?/a/p
pa href=https://t.co/3rkxUchPyu?amp=1 target=_blankThe Jones Act hurts domestic crude oil shipping/a/p
pa href=https://reason.org/commentary/the-negative-impacts-of-massachusetts-flavored-tobacco-ban/ target=_blankMassachusetts banned flavored tobacco and you’ll never guess what happened next!/a/p
pa href=https://marginalrevolution.com/marginalrevolution/2020/12/covid-19-as-a-ramsey-tax-problem.html?utm_source=feedburneramp;utm_medium=feedamp;utm_campaign=Feed%3A+marginalrevolution%2Ffeed+%28Marginal+Revolution%29 target=_blankCOVID-19 as anbsp;Ramsey tax problem/a/p
pa href=https://www.mckinsey.com/featured-insights/coronavirus-leading-through-the-crisis/charting-the-path-to-the-next-normal/what-share-of-the-us-population-needs-to-get-vaccinated-against-covid-19?cid=other-eml-alt-chr-mckamp;hlkid=1b6adc9912a1447dbc8a17b02199b64eamp;hctky=12382254amp;hdpid=2b25e32d-b711-4d36-a7e3-695bf8bbfe18 target=_blankWhat share of the USA needs to get vaccinated for COVID-19 herd immunity to kick in?/a/p
pa href=https://t.co/kEegqViZYS?amp=1 target=_blankStudy: working from home will stick/a/p
pa href=https://t.co/faF9kkNNgx?amp=1 target=_blankHawaii is paying for remote workers to move there/a/p
pa href=https://ew.com/movies/warner-bros-2021-hbo-max/ target=_blankMovies, they’re a’ changin/a/p
pa href=https://www.bloomberg.com/news/articles/2020-12-02/globalization-is-alive-and-kicking-in-trade-s-big-2020-comeback target=_blankTrade’s making anbsp;comeback/a/p
pa href=https://www.piie.com/blogs/realtime-economic-issues-watch/washington-consensus-stands-test-time-better-populist-policies target=_blankThe “Washington Consensus” worked pretty well, actually/a/p
pa href=https://www.cato.org/blog/immigrant-citizens-didnt-shift-counties-toward-supporting-trump-2020-election-0 target=_blankDid immigrants vote Trump in 2020?/a/p
pa href=https://t.co/twunctCZUd?amp=1 target=_blank“To me, this is anbsp;book about the potentially transformative power of human freedom”/a/p
pa href=https://www.econlib.org/freedom-the-harm-principle-and-the-covid-vaccine/ target=_blankWhat’s the “libertarian” position on state vaccination efforts?/a/p
pa href=https://www.sciencealert.com/bizarre-jelly-blob-glimpsed-off-puerto-rican-coast-in-first-of-its-kind-discovery target=_blankFinally, new gelatinous blob/a/p
/div
Scott Lincicome is an international trade attorney, an adjunct scholar at the Cato Institute, and anbsp;visiting lecturer at Duke University Law School.